AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
Gastroenterology
; 163(5)20221101.
Artigo
em Inglês
| BIGG
| ID: biblio-1412180
Biblioteca responsável:
BR1.1
ABSTRACT
Pharmacological management of obesity improves outcomes and decreases the risk of obesity-related complications. This American Gastroenterological Association guideline is intended to support practitioners in decisions about pharmacological interventions for overweight and obesity. A multidisciplinary panel of content experts and guideline methodologists used the Grading of Recommendations Assessment, Development and Evaluation framework to prioritize clinical questions, identify patient-centered outcomes, and conduct an evidence synthesis of the following agents semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate extended-release (ER), naltrexone-bupropion ER, orlistat, phentermine, diethylpropion, and Gelesis100 oral superabsorbent hydrogel. The guideline panel used the evidence-to-decision framework to develop recommendations for the pharmacological management of obesity and provided implementation considerations for clinical practice. The guideline panel made 9 recommendations. The panel strongly recommended the use of pharmacotherapy in addition to lifestyle intervention in adults with overweight and obesity (body mass index ≥30 kg/m2, or ≥27 kg/m2 with weight-related complications) who have an inadequate response to lifestyle interventions. The panel suggested the use of semaglutide 2.4 mg, liraglutide 3.0 mg, phentermine-topiramate ER, and naltrexone-bupropion ER (based on moderate certainty evidence), and phentermine and diethylpropion (based on low certainty evidence), for long-term management of overweight and obesity. The guideline panel suggested against the use of orlistat. The panel identified the use of Gelesis100 oral superabsorbent hydrogel as a knowledge gap. In adults with overweight and obesity who have an inadequate response to lifestyle interventions alone, long-term pharmacological therapy is recommended, with multiple effective and safe treatment options.
C - Todos os direitos reservados
Assuntos
Texto completo:
Disponível
Coleções:
Bases de dados temática
Contexto em Saúde:
Agenda de Saúde Sustentável para as Américas 2030 - ASSA2030
/
ODS3 - Saúde e Bem-Estar
Base de dados:
BIGG
Assunto principal:
Resistência à Insulina
/
Fatores de Risco de Doenças Cardíacas
/
Obesidade
Tipo de estudo:
Estudo de etiologia
/
Guia de prática clínica
/
Estudo prognóstico
/
Fatores de risco
Idioma:
Inglês
Revista:
Gastroenterology
Ano de publicação:
2022
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS